Close Menu
healthylife7.comhealthylife7.com

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    September is Self

    September 1, 2026

    Mindfulness may lower blood pressure in just 8 weeks

    September 1, 2026

    Crunch Franchise Brings Next-Generation Fitness Experience to Rockledge, Florida

    September 1, 2026
    Facebook X (Twitter) Instagram
    Trending
    • September is Self
    • Mindfulness may lower blood pressure in just 8 weeks
    • Crunch Franchise Brings Next-Generation Fitness Experience to Rockledge, Florida
    • Pure Genius Protein Launches Protein + Fiber Shots To Fill Nutrition Gap
    • All the News That’s Fit: Dollar store foods, hair-raising syndrome and pesticides on produce
    • Novo Nordisk launches Wegovy weight
    • Explore Young People’s Daily Lives: A Complete Guide to Understanding Modern Youth Lifestyles Through Their Fridges
    • Gene-editing research reaches younger children with blood disorders
    Facebook X (Twitter) Instagram
    healthylife7.comhealthylife7.com
    • Home
    • Fitness
    • Health
    • Nutrition
    • Lifestyle
    • Conditions
    • Mental Health
    • Weight Loss
    • Wellness Tips
    Tuesday, September 1
    healthylife7.comhealthylife7.com
    Home»Wellness Tips»Can Pfizer (NYSE:PFE) Rebuild Momentum as Oncology and Obesity Ambitions Take Shape?
    Wellness Tips

    Can Pfizer (NYSE:PFE) Rebuild Momentum as Oncology and Obesity Ambitions Take Shape?

    healthylife7By healthylife7September 1, 2026No Comments16 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
    Can Pfizer (NYSE:PFE) Rebuild Momentum as Oncology and Obesity Ambitions Take Shape?
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    S&P 500LLY(USD1156.73-1.52%)UNH(USD389.41-0.90%)MRK(USD147.76-0.40%)PFE(USD28.46+1.79%)
    11 min read | September 01, 2026 04:15 AM PDT | By
    Anmol Khazanchi
    Google News:

    thumbnail

    Is NextEra Energy (NYSE:NEE) Riding The AI Power-Demand Wave?

    thumbnail

    Is Duke Energy (NYSE:DUK) Positioned For The Power-Demand Boom?

    thumbnail

    Is Southern Company (NYSE:SO) A Core Name In The Power-Demand Era?

    thumbnail

    Is Dominion Energy (NYSE:D) At The Heart Of The Data-Center Boom?

    Make Kalkine Media

    My Trusted Source

    Highlights

    • A healthcare rally lifted the drug sector, and the enterprise advanced with its peers.
    • An expanding oncology pipeline anchors the enterprise’s growth ambitions.
    • A move into obesity medicine broadened the enterprise’s metabolic reach.

    Pfizer (NYSE:PFE)HealthcarePfizer Inc (NYSE:PFE)28.46
    USD+0.5001.788%Last Updated at: 2026-08-31T20:28:00Z
    drew attention as the healthcare sector logged its strongest week since June and the enterprise pressed ahead with an expanding oncology pipeline and fresh ambitions in obesity medicine, spotlighting a diversified pharmaceutical giant working to rebuild momentum after its pandemic-era surge faded. The advance came amid a broad sector rally sparked by clinical-trial momentum, and it framed the enterprise’s effort to pivot toward the growth areas reshaping modern medicine.

    A Sector-Wide Rally

    The immediate backdrop was a burst of strength across healthcare, traced largely to a breakthrough late-stage cancer-vaccine result that reignited enthusiasm for the sector’s innovation engine. The rally lifted names across pharmaceuticals and biotech, marking the group’s best week since June. For a diversified drugmaker such as this enterprise, whose portfolio spans oncology, vaccines, and specialty medicines, a broad advance in the sector tends to lift the stock even when the spark originates elsewhere. The episode underscored how tightly the drug sector can move when innovation headlines shift sentiment across the space.

    A Diversified Drug Giant

    The enterprise ranks among the largest pharmaceutical companies in the world, with a portfolio spanning oncology, vaccines, immunology, and specialty medicines. Its pandemic-era vaccines and treatments drove an enormous surge in revenue, which has since faded as demand normalized, leaving the enterprise to rebuild growth through its broader pipeline. That transition has defined the enterprise’s recent chapter, as it deploys the cash generated during the pandemic to reshape its portfolio toward areas with durable demand. The breadth of its franchise gives it multiple avenues to pursue that renewal across the healthcare economy.

    Oncology at the Center

    Cancer medicine has become the centerpiece of the enterprise’s growth ambitions. Through a landmark acquisition of a cancer-focused biotech and heavy internal spending, the enterprise assembled a broad oncology pipeline spanning solid tumors and blood cancers. That push aims to establish the enterprise among the leaders in cancer treatment over the coming years, a market defined by intense innovation and enormous unmet need. Advancing its oncology candidates through late-stage trials has taken priority, as the enterprise works to build a franchise capable of driving growth as older medicines face generic competition.

    A Move Into Obesity

    The enterprise has also moved to establish a foothold in the surging market for metabolic and obesity medicines. Through an acquisition of a company developing a long-acting injectable weight-management therapy, the enterprise added a candidate to a category that has reshaped the pharmaceutical sector. That move reflects a recognition that metabolic medicine has become one of the defining growth themes in healthcare, and the enterprise aims to carve out a presence alongside the established leaders. Building a competitive obesity candidate would broaden the enterprise’s reach into a market with vast and still-growing demand.

    The Innovation Backdrop

    The rally that lifted the sector traced to a landmark late-stage cancer-vaccine result, part of a broader wave of oncology and messenger-RNA momentum reshaping enthusiasm for healthcare innovation. That wave carries direct relevance for the enterprise, which has staked much of its growth ambition on cancer medicine. Advances that expand the arsenal against serious disease validate the heavy spending flowing into oncology across the sector, and they reinforce the demand backdrop for the therapies the enterprise is developing. The innovation wave thus strengthens the long-run case for the enterprise’s pivot toward cancer treatment.

    Market Environment and Rates

    The advance unfolded against a shifting rate backdrop, with softer jobs and inflation readings reshaping the debate over borrowing costs ahead of the coming central-bank decision. Healthcare has drawn support as a corner of the market prized for innovation and steady demand, and the sector logged its strongest week since June amid a wave of trial momentum. As capital rotated toward sectors offering dependable growth, large drugmakers with deep pipelines drew renewed attention. That backdrop framed the sector rally that lifted the enterprise alongside its peers.

    Competitive Landscape

    The enterprise operates within a pharmaceutical sector populated by giants. Eli Lilly (NYSE:LLY)HealthcareEli Lilly and Company (NYSE:LLY)1156.73
    USD-17.8801.522%Last Updated at: 2026-08-31T20:26:00Z
    has surged on the strength of metabolic medicines, Merck (NYSE:MRK)HealthcareMerck & Company Inc (NYSE:MRK)147.76
    USD-0.5900.398%Last Updated at: 2026-08-31T20:05:00Z
    anchors its franchise in cancer immunotherapy and vaccines, and managed-care leader UnitedHealth Group (NYSE:UNH)HealthcareUnitedHealth Group Incorporated (NYSE:UNH)389.41
    USD-3.5400.901%Last Updated at: 2026-08-31T20:15:00Z
    sits on the benefits side of healthcare. Those peers occupy overlapping corners of the sector, and all move within the same currents when innovation headlines shift sentiment. The enterprise stands apart for the scale of its transition, as it works to rebuild growth through oncology and obesity after its pandemic-era franchise faded, a pivot that defines its recent chapter.

    Operational Focus

    Management has centered its message on advancing its oncology pipeline, integrating acquisitions, and controlling costs as it works to rebuild growth. Deploying the cash generated during the pandemic to acquire and develop new medicines has taken priority, alongside cost-cutting aimed at improving margins after the revenue surge faded. Heavy spending on research and development underpins a pipeline spanning cancer, obesity, vaccines, and specialty medicines. That focus on portfolio renewal and disciplined operations reflects the scale of the transition the enterprise faces as it works to define its next chapter of growth.

    Industry Challenges

    Challenges remain material. Drug development is costly and uncertain, and the enterprise faces the task of replacing revenue from medicines nearing the end of their patent protection. Its recent oncology and obesity moves carry integration and execution challenges, and the metabolic market it is entering is already crowded with established leaders. Pricing scrutiny weighs on the entire pharmaceutical sector, and the fading of pandemic-era demand has pressured results. Regulatory and reimbursement dynamics add further variables. These headwinds frame why pipeline execution and cost discipline remain central to the enterprise’s approach.

    Broader Market Relevance

    A member of the S&P 500, the enterprise trades as a bellwether for the diversified pharmaceutical sector and for the broader push to translate innovation into durable growth. Its moves often signal shifting sentiment across the space, drawing attention whenever its pipeline advances or its transition draws scrutiny. The current stretch, with a healthcare rally lifting the sector and its oncology ambitions in view, has kept the stock in focus. Within the wider universe of Healthcare Stocks, the enterprise stands out for the scale of its portfolio and the ambition of its pivot toward oncology and obesity medicine.

    Life After the Pandemic Surge

    The enterprise’s recent chapter has been defined by the fading of its pandemic-era surge. Its vaccines and treatments drove an enormous, temporary boom in revenue, which has since normalized as demand receded. That transition left the enterprise to rebuild growth through its broader pipeline, deploying the cash generated during the pandemic to reshape its portfolio. Managing the decline of pandemic-related revenue while building new engines of growth has become the central challenge of the enterprise’s current era, shaping its acquisitions, spending, and strategic focus across oncology, obesity, and specialty medicine.

    The Oncology Acquisition

    A landmark acquisition of a cancer-focused biotech reshaped the enterprise’s oncology ambitions. That deal brought a portfolio of cancer medicines and a deep pipeline spanning solid tumors and blood cancers, positioning the enterprise to compete among the leaders in cancer treatment. Integrating such a large acquisition carries execution challenges, from combining research operations to advancing candidates through late-stage trials. Yet the move reflects the enterprise’s conviction that oncology represents a durable engine of growth, a field defined by intense innovation and enormous unmet need. Building out that franchise has become central to the enterprise’s strategy for renewal.

    Building an Obesity Presence

    The enterprise has moved to establish a foothold in the surging market for metabolic and obesity medicines. Through an acquisition of a company developing a long-acting injectable weight-management therapy, the enterprise added a candidate to a category reshaping the pharmaceutical sector. That move reflects recognition that metabolic medicine has become one of the defining growth themes in healthcare. Carving out a presence alongside the established leaders will demand successful development and manufacturing at scale, yet the market’s vast and growing demand rewards those who can compete. The obesity push broadens the enterprise’s reach into a high-growth field.

    A Broad and Diversified Portfolio

    Beyond oncology and obesity, the enterprise commands a broad portfolio spanning vaccines, immunology, and specialty medicines. Its established vaccines protect against a range of diseases, while its specialty medicines address serious conditions across the care spectrum. That diversification broadens the enterprise’s foundation, spreading exposure across multiple therapeutic areas and generating steady revenue that funds its pivot toward growth. The breadth of the portfolio reflects decades of research across many fields, giving the enterprise multiple avenues to pursue renewal. That diversified base cushions the enterprise as it works to replace the revenue lost when its pandemic-era franchise faded.

    Patent Timelines and Renewal

    Like all large drugmakers, the enterprise faces the challenge of patent timelines that eventually expose blockbuster medicines to generic competition. Several established medicines approach the end of their patent protection over the coming years, pressuring the enterprise to build new sources of growth. That reality drives the push into oncology and obesity, as the enterprise works to establish franchises capable of replacing revenue from aging medicines. Managing the patent cliff has become a defining feature of the enterprise’s strategy, shaping its acquisitions, pipeline priorities, and spending as it works to sustain momentum across a shifting portfolio.

    Research Spending and Innovation

    Heavy spending on research and development underpins the enterprise’s effort to rebuild growth. That spending funds a pipeline spanning cancer, obesity, vaccines, and specialty medicines, reflecting the enterprise’s determination to translate science into durable franchises. Sustaining a stream of new medicines demands continuous innovation, and the enterprise has channeled its pandemic-era cash into both acquisitions and internal research. That focus on innovation reflects the reality that pharmaceutical growth depends on a steady flow of successful medicines. The depth of the enterprise’s research effort will shape its ability to define a new chapter of growth across the healthcare sector.

    Vaccines as a Steady Base

    The enterprise’s established vaccine franchise provides a steady base of revenue across its diversified portfolio. Its vaccines protect against a range of infectious diseases, generating dependable demand governed by public-health needs rather than discretionary spending. That steady base cushions the enterprise as it navigates the fading of its pandemic-era surge and works to rebuild growth through oncology and obesity. The vaccine arm reflects decades of research and manufacturing expertise, giving the enterprise a durable foundation across the broader healthcare economy. Maintaining and expanding that franchise remains an important piece of the enterprise’s strategy for sustaining revenue through its portfolio transition.

    Cost Discipline After the Boom

    The fading of pandemic-era demand prompted the enterprise to sharpen its focus on cost discipline. Programs aimed at cutting expenses and improving margins have accompanied the enterprise’s push into oncology and obesity, reflecting a recognition that rebuilding growth demands both new medicines and operational efficiency. Managing costs while funding a broad pipeline requires careful balance, and the enterprise has worked to streamline operations without starving its research effort. That focus on discipline reflects the scale of the transition the enterprise faces, as it works to translate its diversified portfolio into durable growth after the extraordinary boom and subsequent normalization of pandemic-related revenue.

    Navigating Pricing Scrutiny

    Pricing scrutiny weighs on the entire pharmaceutical sector, and the enterprise operates amid persistent attention to the cost of medicines. Public and political focus on drug pricing shapes the environment in which the enterprise develops and markets its therapies, influencing reimbursement and access. Navigating that scrutiny demands careful engagement with payers, regulators, and lawmakers, alongside strategies to demonstrate the value of its medicines. The enterprise’s diversified portfolio spreads its exposure across many therapies, cushioning it against pressure on any single product. Managing pricing dynamics has become a defining feature of operating in the sector, and the enterprise’s breadth and pipeline depth position it to adapt as the environment evolves.

    Reading the Session

    The attention reflected a broad healthcare rally and the enterprise’s advancing ambitions in oncology and obesity, a backdrop that plays directly to its effort to rebuild growth after its pandemic surge faded. Whether the momentum extends will hinge on pipeline outcomes, integration of its acquisitions, and the pace of competition, yet the enterprise’s diversified franchise and its push into high-growth categories leave it closely tied to the innovation themes reshaping healthcare. The general information here is provided for reference only and does not constitute financial advice; readers should conduct independent research before making any decisions related to the healthcare sector or the names discussed.

    To keep reading, please log in to your account, create a free account, or simply fill out the form below

    `;

    $(document).find(“#signup_form button[type=’submit’]”).closest(“button”).before(htmlMsg);

    setTimeout(() => {
    $(“.errorDiv”).fadeOut(300, function () { $(this).remove(); });
    }, 3000);
    }

    jQuery.validator.addMethod(“validName”, function(value, element) {
    value = value.trim();
    return this.optional(element) || /^(?=(?:.*[A-Za-z]){2,})[A-Za-z]+(?: [A-Za-z]+)*$/.test(value);
    }, “Please enter at least 2 letters (letters and single spaces only).”);

    function updateResendOtpTimer() {
    if (countdown > 0) {
    countdown–;
    $(“#timer”).text(countdown + “s”);
    } else {
    clearInterval(timer);
    countdown = 30;
    otpSent = false;
    $(“#resendOtpText”).hide();
    $(“#sendOtpLink”).show();
    }
    }

    function sendOtp() {
    const phoneInputVal = $(document).find(“#lead_phone”).val().trim();
    const dialCode = iti.getSelectedCountryData().dialCode;
    const allowedCountries = [“44”, “61”, “1”, “91”, “64”];

    if (!phoneInputVal) return showMessage(“error”, “Please enter a mobile number.”);
    if (!iti.isValidNumber()) return showMessage(“error”, “Please enter a valid mobile number.”);
    if (!allowedCountries.includes(dialCode)) return showMessage(“error”, “OTP is only available for “+ [“au”,”gb”,”ca”,”nz”,”us”,”in”,”uk”]);

    if(!otpSent){
    $(document).find(“#lead_otp”).val(“”);
    }

    const phoneNumber = dialCode + phoneInputVal;
    request_id = $(document).find(“#ref_id”).val() || ”;

    otpSent = true;
    $(document).find(“#sendOtpLink”).hide();
    $(document).find(“#resendOtpText”).show();
    //$(document).find(“.otp-form-group”).hide();

    $.ajax({
    url: “https://kalkinemedia.com/a/verification”,
    type: ‘POST’,
    data: { phone_number: phoneNumber, request_id },
    headers: { ‘X-CSRF-TOKEN’: ‘NObvIbQukpUyjPz2psQRIgjmsdWrwkW81HwU2uIb’ },
    success: function (response) {
    if (response.status === “success”) {
    showMessage(“success”, response.message);
    //$(document).find(“.otp-form-group”).show();

    if ($(document).find(“#ref_id”).length) {
    $(document).find(“#ref_id”).val(response.request_id);
    } else {
    $(”).attr({
    type: ‘hidden’,
    id: ‘ref_id’,
    name: ‘ref_id’,
    value: response.request_id
    }).appendTo(‘#signup_form’);
    }

    countdown = 30;
    timer = setInterval(updateResendOtpTimer, 1000);
    } else {
    otpSent = false;
    showMessage(“error”, response.message);
    $(document).find(“#resendOtpText”).hide();
    $(document).find(“#sendOtpLink”).show();
    }
    },
    error: function () {
    otpSent = false;
    showMessage(“error”, “An error occurred. Please try again.”);
    $(document).find(“#resendOtpText”).hide();
    $(document).find(“#sendOtpLink”).show();
    }
    });
    }

    function verifyOtp() {
    $(document).find(“div.otp-form-group div.spinner-border”).removeClass(“d-none”);
    // $(document).find(“div.otp-form-group span#verifyOtpLink”).addClass(“d-none”);

    $.ajax({
    url: “https://kalkinemedia.com/a/verificationChecks”,
    type: ‘POST’,
    data: {
    request_id: $(document).find(“#ref_id”).val(),
    code: $(document).find(“#lead_otp”).val()
    },
    headers: {
    ‘X-CSRF-TOKEN’: ‘NObvIbQukpUyjPz2psQRIgjmsdWrwkW81HwU2uIb’
    },
    success: function(response) {
    $(document).find(“div.otp-form-group div.spinner-border”).addClass(“d-none”);
    if (response.status === “success”) {
    otpVerified = true;
    showMessage(“success”, response.message);
    $(document).find(“#lead_otp”).prop(“disabled”, true);
    // $(document).find(“#signup_form button”).removeClass(“d-none”)
    setTimeout(() => toggleReadNowButton(), 0);
    // if($(“#hotstock_checkbox”).is(“:checked”)){
    // $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, false);
    // }else{
    // $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
    // }

    $(document).find(“#sendOtpLink”).addClass(“d-none”);
    $(document).find(“#resendOtpText”).hide();
    $(document).find(“#verifyOtpLink”).addClass(“d-none”);
    $(document).find(“#successBadge”).removeClass(“d-none”);
    } else {
    otpVerified = false;
    showMessage(“error”, response.message);
    setTimeout(() => toggleReadNowButton(), 0);
    // $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
    // $(document).find(“#verifyOtpLink”).removeClass(“d-none”);
    }
    $(document).find(“#lead_otp”).prop(“disabled”, otpVerified);
    },
    error: function(xhr, status, error) {
    $(document).find(“div.otp-form-group div.spinner-border”).addClass(“d-none”);
    showMessage(“error”, error.message);
    // $(document).find(“#verifyOtpLink”).removeClass(“d-none”);
    $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
    }
    });
    }

    $(document).find(“#sendOtpLink”).on(“click”, sendOtp);

    $(document).on(“input”, “#lead_otp”, function () {
    const otp = $(this).val();
    if (otp.length === 6) {
    verifyOtp();
    }
    });
    // $(document).find(“#verifyOtpLink”).on(“click”, verifyOtp);

    function toggleSendOtpButton() {
    // if (!iti) return;
    const name = $(“#lead_name”).val().trim();
    const email = $(“#lead_email”).val().trim();
    const phone = $(“#lead_phone”).val().trim();
    // const checkbox = $(“#hotstock_checkbox”).is(“:checked”);

    const isNameValid = name.length >= 2 && /^[a-zA-Zs]+$/.test(name);

    // Validate email: basic email format
    const isEmailValid = /^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,}$/.test(email);

    // Validate phone using intlTelInput
    const isPhoneValid = iti && iti.isValidNumber();

    // Checkbox validation: must be checked
    // const isCheckboxChecked = checkbox;

    // If all fields are valid, enable the OTP button
    if (isNameValid && isEmailValid && isPhoneValid) {
    $(document).find(“#sendOtpLink”).css({“opacity”:”1″, “pointer-events”:”auto”});
    } else {
    $(document).find(“#sendOtpLink”).css({“opacity”:”0.5″, “pointer-events”:”none”});
    }

    // const formValid = $(“#signup_form”).valid();
    //const phoneValid = iti.isValidNumber();
    //if (formValid && phoneValid) {
    // $(document).find(“#sendOtpLink”).css({“opacity”:”1″,”pointer-events”:”auto”});
    //$(document).find(“#sendOtpLink”).show();
    //} else {
    // $(document).find(“#sendOtpLink”).css({“opacity”:”0.5″,”pointer-events”:”none”});
    //$(document).find(“#sendOtpLink”).hide();
    // }
    }

    function toggleReadNowButton(){

    const name = $(“#lead_name”).val().trim();
    const email = $(“#lead_email”).val().trim();
    const phone = $(“#lead_phone”).val().trim();

    const isNameValid = name.length >= 2 && /^[a-zA-Zs]+$/.test(name);
    const isEmailValid = /^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+.[a-zA-Z]{2,}$/.test(email);
    const isPhoneValid = iti && iti.isValidNumber();

    checkbox = $(“#hotstock_checkbox”).is(“:checked”);

    const isCheckboxChecked = checkbox;

    if (isNameValid && isEmailValid && isPhoneValid && isCheckboxChecked && otpVerified) {
    $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, false);
    }else{
    $(document).find(“#signup_form button[type=’submit’]”).prop(“disabled”, true);
    }
    }

    $(“#signup_form input”).on(“change”, function () {
    setTimeout(() => toggleSendOtpButton(), 0);
    });

    $(“#lead_name”).on(‘input’, function() {
    this.value = this.value.replace(/s{2,}/g, ‘ ‘);
    this.value = this.value.replace(/[.]/g, ”);
    $(this).valid();
    toggleSendOtpButton();
    });

    $(“#lead_email”).on(‘input’, function() {
    this.value = this.value.replace(/s/g, ”);
    });

    if(enableOTPJS){
    $(“#signup_form input, #signup_form select”).on(“change”, function () {
    setTimeout(() => toggleReadNowButton(), 0);
    });
    }

    $(“#signup_form”).validate({
    errorPlacement: function(error, element) {
    //element.addClass(‘is-invalid’);

    //$(element).siblings(‘.error’).remove();

    //if ($(“.is-invalid”).length === 1) {
    // error.appendTo(element.parent());
    //}

    if (element.attr(“name”) == “lead_name”)
    error.appendTo(“#errordivname”);
    else if (element.attr(“name”) == “lead_email”)
    error.appendTo(“#errordivemail”);
    else if (element.attr(“name”) == “lead_phone”)
    error.appendTo(“#errordivmobile”);
    else if (element.attr(“name”) == “hotstock_checkbox”)
    error.appendTo(“#errordivcheckbox”);
    else if (element.attr(“name”) == “lead_otp”)
    error.appendTo(“#errordivotp”);
    },

    success: function(label, element) {
    $(element).removeClass(‘is-invalid’);
    label.remove();
    },
    rules: {
    lead_name: {
    required: true,
    minlength: 2,
    maxlength:50,
    validName:true
    },
    lead_phone: {
    intlTelNumber: true,
    required: true,
    number: true,
    // validatePhone: true,
    maxlength:12
    },
    lead_email: {
    required: true,
    email: true,
    emailPattern: true
    },
    hotstock_checkbox: {
    required: true,
    },
    lead_otp: {
    required: function() {
    // var selectedCountry = iti.getSelectedCountryData();
    // return selectedCountry.iso2 === ‘gb’;
    var selectedCountry = iti.getSelectedCountryData();
    return selectedCountry.iso2 === ‘gb’ || selectedCountry.iso2 === ‘au’ || selectedCountry.iso2 === ‘ca’ || selectedCountry.iso2 === ‘us’;
    },
    minlength: 6,
    maxlength: 6,
    digits: true
    },
    },

    onkeyup: function(element) {
    this.element(element);
    setTimeout(() => toggleSendOtpButton(), 0);
    },
    onfocusout: function(element) {
    this.element(element);
    setTimeout(() => toggleSendOtpButton(), 0);
    },

    messages: {
    lead_name: {
    required: ‘Please enter valid name.’,
    minlength: ‘Name must be at least 4 characters long.’
    },
    lead_email: {
    required: ‘Please enter a valid email address’,
    email: ‘Please enter a valid email address (e.g., abc@gmail.com)’,
    emailPattern: ‘Please enter a valid email address (e.g., abc@gmail.com)’
    },
    lead_phone: {
    required: ‘Please enter valid mobile number.’
    },
    hotstock_checkbox: {
    required: ‘Please read our Terms and Conditions.’
    },
    lead_otp: {
    required: ‘Valid OTP is required that you’ve received on your number.’
    },
    },

    submitHandler: function(form) {
    event.preventDefault();
    var navigate_url = $(“.navigate_url”).val();
    $(“#signup_form”).find(‘:submit’).html(‘ Loading…’).prop(‘disabled’,true);
    // var countryCode = $(“#signup_form”).find(‘div.iti__selected-dial-code’).html()
    var selectedCountryData = iti.getSelectedCountryData();
    var countryCode = selectedCountryData.iso2;
    var countryCode2 = selectedCountryData.dialCode;
    $(”).attr({
    type: ‘hidden’,
    id: ‘countryCode’,
    name: ‘countryCode’,
    value: countryCode2
    }).appendTo(‘#signup_form’);
    $(”).attr({
    type: ‘hidden’,
    id: ‘countryCodeISO’,
    name: ‘countryCodeISO’,
    value: countryCode
    }).appendTo(‘#signup_form’);

    var url = “https://kalkinemedia.com/a/checkPhoneNumber”;

    url =`${url}/${countryCode2+$(document).find(“#lead_phone”).val()}`

    if (enableOTPJS && !otpVerified) {
    toast_msg(“OTP Verification required”, ‘error’);
    $(“#signup_form”).find(‘:submit’).html(‘Read Now’).prop(‘disabled’, false);
    return
    }

    $.get(url, function(response) {
    if (response.status) {

    $(”).attr({
    type: ‘hidden’,
    id: ‘telesignScore’,
    name: ‘telesignScore’,
    value: response.data.telesign_info ?? “NA”
    }).appendTo(‘#signup_form’);

    $(”).attr({
    type: ‘hidden’,
    id: ‘addrScore’,
    name: ‘addrScore’,
    value: ($(document).find(“#ref_id”).val() !== ” && otpVerified) ? ‘true’: ‘false’
    }).appendTo(‘#signup_form’);

    // if (response.otp_required && $(document).find(“.otp-form-group”).hasClass(“d-none”)) {
    //$(document).find(“.otp-form-group”).removeClass(“d-none”)
    // } else {
    // $(document).find(“.otp-form-group”).addClass(“d-none”)
    // }

    $.ajax({
    headers: {
    ‘X-CSRF-TOKEN’: ‘NObvIbQukpUyjPz2psQRIgjmsdWrwkW81HwU2uIb’
    },
    type: “POST”,
    url: “https://kalkinemedia.com/user/content_block/lead”,
    data: $(form).serialize(),
    dataType: ‘json’,
    success: function(result) {
    if (result.status == 1) {
    window.location.href = result.redirect_url;
    showMessage(“success”, result.message)
    } else {
    showMessage(“error”, result.message)
    $(“#signup_form”).find(‘:submit’).html(
    ‘Updating’).prop(‘disabled’, false);
    }
    }
    });

    }
    }).fail(function(jqXHR, textStatus, errorThrown) {
    // Handle errors
    // console.error(‘Error:’, textStatus, errorThrown);
    });

    return false;
    }
    });
    });

    momentum NYSEPFE oncology Pfizer rebuild
    healthylife7
    • Website

    Related Posts

    Novo Nordisk launches Wegovy weight

    September 1, 2026

    Kelly Osbourne breaks silence on dramatic weight loss: ‘I wasn’t well’

    September 1, 2026

    Inside Amy Slaton’s Weight Loss Journey

    September 1, 2026
    Leave A Reply Cancel Reply

    Health
    Lifestyle

    September is Self

    By healthylife7September 1, 20260

    Fla. (WWSB) – Amy Schmidt is a podcaster, author, and founder and CEO of “Fearlessly Facing Fifty.” She said self-care needs to be bigger than something bought or scheduled into a calendar

    Mindfulness may lower blood pressure in just 8 weeks

    September 1, 2026

    Crunch Franchise Brings Next-Generation Fitness Experience to Rockledge, Florida

    September 1, 2026

    Pure Genius Protein Launches Protein + Fiber Shots To Fill Nutrition Gap

    September 1, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Fitness

    Opinion: The FDA must put biotech at its center or continue to cede early research to China

    July 6, 2026

    Inside Elevance’s digital chronic disease management strategy

    July 6, 2026

    Best, Worst States For Well

    July 6, 2026

    What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

    July 6, 2026

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us

    Welcome to HealthyLife7.com, your trusted source for reliable health, wellness, fitness, and lifestyle information. Our mission is to help people make informed decisions about their health by providing clear, practical, and easy-to-understand content.

    At HealthyLife7.com, we believe that good health starts with the right knowledge. Whether you're looking for healthy eating tips, fitness advice, mental wellness strategies, weight management guidance, or information about common health conditions, our goal is to deliver valuable content that supports a healthier lifestyle.

    Fitness

    September is Self

    September 1, 2026

    Mindfulness may lower blood pressure in just 8 weeks

    September 1, 2026

    Crunch Franchise Brings Next-Generation Fitness Experience to Rockledge, Florida

    September 1, 2026
    Health

    Opinion: The FDA must put biotech at its center or continue to cede early research to China

    July 6, 2026

    Inside Elevance’s digital chronic disease management strategy

    July 6, 2026

    Best, Worst States For Well

    July 6, 2026
    Facebook X (Twitter) Instagram Pinterest
    • About Us
    • Contact us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    © 2026 healthylife7.com. Designed by Pro.

    Type above and press Enter to search. Press Esc to cancel.